Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells 200,000 Shares of Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Ventures L.P. 5Am sold 200,000 shares of the business’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $8.80, for a total value of $1,760,000.00. Following the completion of the transaction, the insider owned 2,963,066 shares of the company’s stock, valued at $26,074,980.80. This represents a 6.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Entrada Therapeutics Stock Performance

Shares of TRDA traded up $0.35 during mid-day trading on Tuesday, hitting $8.82. 330,970 shares of the company traded hands, compared to its average volume of 187,747. The stock has a market cap of $337.10 million, a price-to-earnings ratio of -3.54 and a beta of -0.09. The stock has a 50-day moving average price of $6.30 and a two-hundred day moving average price of $6.66. Entrada Therapeutics, Inc. has a 1 year low of $4.93 and a 1 year high of $21.79.

Entrada Therapeutics (NASDAQ:TRDA) last announced its earnings results on Thursday, November 6th. The company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.02). Entrada Therapeutics had a negative net margin of 168.16% and a negative return on equity of 26.42%. The business had revenue of $1.61 million for the quarter, compared to analysts’ expectations of $8.62 million. On average, analysts forecast that Entrada Therapeutics, Inc. will post 1.12 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on TRDA shares. Zacks Research raised Entrada Therapeutics to a “hold” rating in a research note on Friday, August 8th. Roth Capital set a $13.00 price target on shares of Entrada Therapeutics in a report on Thursday, November 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Entrada Therapeutics in a research note on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of Entrada Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $20.67.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Jacobs Levy Equity Management Inc. boosted its holdings in Entrada Therapeutics by 43.1% in the third quarter. Jacobs Levy Equity Management Inc. now owns 315,810 shares of the company’s stock valued at $1,832,000 after purchasing an additional 95,074 shares during the last quarter. NewEdge Advisors LLC acquired a new position in shares of Entrada Therapeutics in the 3rd quarter valued at about $82,000. XTX Topco Ltd acquired a new position in shares of Entrada Therapeutics in the 3rd quarter valued at about $540,000. Sherbrooke Park Advisers LLC purchased a new stake in shares of Entrada Therapeutics in the third quarter worth about $108,000. Finally, Qube Research & Technologies Ltd grew its holdings in Entrada Therapeutics by 115.3% during the third quarter. Qube Research & Technologies Ltd now owns 287,873 shares of the company’s stock worth $1,670,000 after acquiring an additional 154,143 shares during the period. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.